Cardiopulmonary Exercise Testing is an operative way
to assess patient’s cardiovascular & pulmonary diseases. The tests involve
blood pressure, electrocardiography analysis, etc. It is used for assessing the
exercise capacity and predict outcome in patients with heart failure &
other cardiac conditions. It provides a valuation of integrative exercise
responses to the patients suffering from cardiovascular, pulmonary, and
skeletal muscle systems. It helps cardiac patients to control & manage
their heart conditions. It is a low risk investigation which permits precise,
vibrant valuation of cardiac and pulmonary performance.
According to study, “Cardiopulmonary
Exercise Testing Market Research Report by Product (Echocardiogram, Pulse
Oximeters, Stress Blood Pressure Monitors, and Others), End-user
(Hospital/Clinical Laboratories, Diagnostic Centers, Ambulatory Centers, and
Others), and Region (APAC, Europe, North America, RoW)-Global Forecast to 2023”
the key companies operating in the cardiopulmonary exercise testing market are
COSMED srl, Nihon Kohden Corporation, GE Healthcare, Cardinal Health, Masimo
Corporation, Halma plc., Hill-Rom Holdings, Inc., Schiller AG, Vyaire Medical,
Inc., Koninklijke Philips N.V., MGC Diagnostics Corporation. The key strategies
that players provide to influence market growth include research &
development, vide product portfolio and strategic business procurements.
Based on product type, cardiopulmonary exercise
testing market is segmented into Cardiopulmonary Exercise Testing (CPET)
Systems, pulse oximeters, Single-Photon Emission Computed Tomography (SPECT),
stress blood pressure monitors and echocardiogram. CPET segment dominate the
market owing to rise in incidence of ischemia. In addition, based on end-user,
market is segmented into hospitals & clinics, ambulatory centres,
diagnostic centres and others. The rise in rate of cardiovascular disorders
globally has supported the cardiopulmonary exercise testing market growing
extensively.
The hospitals & clinics segment is expected to
witness substantial growth due to rise in treatment of heart diseases &
coronary diseases and growth in need for diagnosis during the forecast period.
The cardiopulmonary exercise testing market is
driven by rise in cardiovascular & respiratory system-related diseases,
followed by increase in patient population, rise in adoption of early
diagnostic practices, increase in healthcare spending, high disposable income
per individual, rise in demand for high value low volume product, growth in
developments in advanced medical treatment options, increase in awareness
programs and growth in research & development (R&D). However, growth in
regulatory affairs, lack of expertise among healthcare professionals and high
cost of instruments may impact the market. Moreover, rise in emerging markets
and growth in innovations in the new product launches are key opportunities for
market.
Based on geography, the American region holds major
share, followed by European region in cardiopulmonary exercise testing market
owing to rise in prevalence of coronary artery diseases (angina pectoris and
acute myocardial infarction), presence of major manufacturers, rise in
availability of cutting-edge medical technology, improvement in economies and
rise in government initiatives in the region. The Asian-Pacific region is
expected to witness lucrative growth due to low manufacturing cost, rise in
investments by the American & European market giants and growth in
healthcare infrastructure over the forecast period. The global market is estimated
to reach the valuation of US $2248.21 million by growing at a CAGR of 5.75%
during the forecast period (2018- 2023).
To
know more, click on the link below:-
Contact
Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment